Repirinast

This classification denotes a histamine-1 receptor antagonist with the molecular formula C20H21NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4K8KA8B61G, chemically known as 4h-pyrano(3,2-c)quinoline-2-carboxylic acid, 5,6-dihydro-7,8-dimethyl-4,5-dioxo-, isopentyl ester but generally known as repirinast, which bears US NIH Compound Identifier 5050. European Medicines Agency schedules Repirinast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10281MIG. The term REPIRINAST is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). REPIRINAST is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule repirinast under HS 29349990 and SITC 51579. As of Q4 2014, REPIRINAST remains the US FDA Preferred Term for this commodity. Repirinast bears US NLM identifiers UMLS ID C0073071 and NCI Concept Code C73053. SMILES: O1C2C3C([NH]C(=O)C2C(=O)CC1C(=O)OCCC(C)C)C(C(CC3)C)C.